TNFR1-dependent regulation of myeloid cell function in experimental autoimmune uveoretinitis

Journal of Immunology

Volumn 183, Issue 4, 2009, Pages 2321-2329

  Raveney, Ben J E ^a,b   Copland, David A ^a   Dick, Andrew D ^a   Nicholson, Lindsay B ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; RECOMBINANT HUMAN TUMOR NECROSIS FACTOR BINDING PROTEIN 1; RECOMBINANT HUMAN TUMOR NECROSIS FACTOR-BINDING PROTEIN-1; TNFRSF1A PROTEIN, MOUSE; TUMOR NECROSIS FACTOR DECOY RECEPTOR;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; AUTOCRINE EFFECT; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BONE MARROW CELL; CELL COUNT; CELL EXPANSION; CELL FUNCTION; CELL ISOLATION; CELL PROLIFERATION; DISEASE COURSE; EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; FLOW CYTOMETRY; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; LEUKOCYTE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINA; T LYMPHOCYTE; TH1 CELL; TH17 CELL; UVEORETINITIS; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CELL CULTURE; CELL MOTION; FEMALE; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; RETINITIS; T LYMPHOCYTE SUBPOPULATION; UVEITIS;

AMINO ACID SEQUENCE; ANIMALS; AUTOIMMUNE DISEASES; CELL MOVEMENT; CELLS, CULTURED; FEMALE; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; MYELOID CELLS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RETINITIS; T-LYMPHOCYTE SUBSETS; TUMOR NECROSIS FACTOR DECOY RECEPTORS; UVEITIS;

EID: 70149093033     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901340     Document Type: Article

References (46)

1. Forrester, J. V., J. Liversidge, H. S. Dua, A. Dick, F. Harper, and P. G. McMenamin. 1992. Experimental autoimmune uveoretinitis: a model system for immunointervention: a review. Curr. Eye Res. 11 Suppl: 33-40.
2. Dick, A. D., J. V. Forrester, J. Liversidge, and A. P. Cope. 2004. The role of tumour necrosis factor (TNF-α) in experimental autoimmune uveoretinitis (EAU). Prog. Retin. Eye Res. 23: 617-637.
3. de Smet, M. D., and C. C. Chan. 2001. Regulation of ocular inflammation: what experimental and human studies have taught us. Prog. Retin. Eye Res. 20: 761-797.
4. Caspi, R. R. 2003. Regulation, counter-regulation, and immunotherapy of autoimmune responses to immunologically privileged retinal antigens. Immunol. Res. 27: 149-160.
5. + T cells in patients with posterior segment intraocular inflammation. Invest. Ophthalmol. Visual Sci. 45: 170-176.
6. Guyver, C. J., D. A. Copland, C. J. Calder, A. Sette, J. Sidney, A. D. Dick, and L. B. Nicholson. 2006. Mapping immune responses to mRBP-3 1-16 peptide with altered peptide ligands. Invest. Ophthalmol. Visual Sci. 47: 2027-2035.
7. Caspi, R. R., F. G. Roberge, C. C. Chan, B. Wiggert, G. J. Chader, L. A. Rozenszajn, Z. Lando, and R. B. Nussenblatt. 1988. A new model of autoimmune disease: experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J. Immunol. 140: 1490-1495.
8. Avichezer, D., P. B. Silver, C. C. Chan, B. Wiggert, and R. R. Caspi. 2000. Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype. Invest. Ophthalmol. Visual Sci. 41: 127-131. (Pubitemid 30036558)
9. Caspi, R. R., C. C. Chan, B. Wiggert, and G. J. Chader. 1990. The mouse as a model of experimental autoimmune uveoretinitis (EAU). Curr. Eye Res. 9 Suppl: 169-174.
10. Kerr, E. C., B. J. Raveney, D. A. Copland, A. D. Dick, and L. B. Nicholson. 2008. Analysis of retinal cellular infiltrate in experimental autoimmune uveoretinitis reveals multiple regulatory cell populations. J. Autoimmun. 31: 354-361.
11. Copland, D. A., M. S. Wertheim, W. J. Armitage, L. B. Nicholson, B. J. Raveney, and A. D. Dick. 2008. The clinical time-course of experimental autoimmune uveoretinitis using topical endoscopic fundal imaging with histologic and cellular infiltrate correlation. Invest. Ophthalmol. Visual Sci. 49: 5458-5465.
12. Hoey, S., P. S. Grabowski, S. H. Ralston, J. V. Forrester, and J. Liversidge. 1997. Nitric oxide accelerates the onset and increases the severity of experimental autoimmune uveoretinitis through an IFN-γ-dependent mechanism. J. Immunol. 159: 5132-5142.
13. Ding, A. H., C. F. Nathan, and D. J. Stuehr. 1988. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J. Immunol. 141: 2407-2412.
14. Calder, C. J., L. B. Nicholson, and A. D. Dick. 2005. A selective role for the TNF p55 receptor in autocrine signaling following IFN-γ stimulation in experimental autoimmune uveoretinitis. J. Immunol. 175: 6286-6293.
15. van der Veen, R. C., T. A. Dietlin, J. Dixon Gray, and W. Gilmore. 2000. Macrophage-derived nitric oxide inhibits the proliferation of activated T helper cells and is induced during antigenic stimulation of resting T cells. Cell Immunol. 199: 43-49.
16. Raveney, B. J., D. A. Copland, L. B. Nicholson, and A. D. Dick. 2008. Fingolimod (FTY720) as an acute rescue therapy for intraocular inflammatory disease. Arch. Ophthalmol. 126: 1390-1395.
17. Copland, D. A., C. J. Calder, B. J. Raveney, L. B. Nicholson, J. Phillips, H. Cherwinski, M. Jenmalm, J. D. Sedgwick, and A. D. Dick. 2007. Monoclonal antibody-mediated CD200 receptor signaling suppresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis. Am. J. Pathol. 171: 580-588.
18. Raveney, B. J., C. M. Richards, M. L. Aknin, D. A. Copland, B. R. Burton, E. C. Kerr, L. B. Nicholson, N. A. Williams, and A. D. Dick. 2008. The B subunit of Escherichia coli heat-labile enterotoxin inhibits Th1 but not Th17 cell responses in established autoimmune uveoretinitis. Invest. Ophthalmol. Visual Sci. 49: 4008-4017.
19. Nicholson, L. B., B. J. Raveney, and M. Munder. 2009. Monocyte dependent regulation of autoimmune inflammation. Curr. Mol. Med. 9: 23-29.
20. van der Veen, R. C., T. A. Dietlin, L. Pen, J. D. Gray, and F. M. Hofman. 2000. Antigen presentation to Th1 but not Th2 cells by macrophages results in nitric oxide production and inhibition of T cell proliferation: interferon-γ is essential but insufficient. Cell Immunol. 206: 125-135.
21. Rodriguez, P. C., and A. C. Ochoa. 2008. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol. Rev. 222: 180-191.
22. Rodriguez, P. C., A. H. Zea, K. S. Culotta, J. Zabaleta, J. B. Ochoa, and A. C. Ochoa. 2002. Regulation of T cell receptor CD3ζ chain expression by L-arginine. J. Biol. Chem. 277: 21123-21129.
23. Ezernitchi, A. V., I. Vaknin, L. Cohen-Daniel, O. Levy, E. Manaster, A. Halabi, E. Pikarsky, L. Shapira, and M. Baniyash. 2006. TCRζ down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J. Immunol. 177: 4763-4772.
24. + T cells. Blood 96: 3838-3846.
25. Robertson, M. J., L. P. Erwig, J. Liversidge, J. V. Forrester, A. J. Rees, and A. D. Dick. 2002. Retinal microenvironment controls resident and infiltrating macrophage function during uveoretinitis. Invest. Ophthalmol. Visual Sci. 43: 2250-2257.
26. Miller, S. D., E. J. McMahon, B. Schreiner, and S. L. Bailey. 2007. Antigen presentation in the CNS by myeloid dendritic cells drives progression of relapsing experimental autoimmune encephalomyelitis. Ann. NY Acad. Sci. 1103: 179-191.
27. + myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 113: 3190-3197.
28. Umemura, N., M. Saio, T. Suwa, Y. Kitoh, J. Bai, K. Nonaka, G. F. Ouyang, M. Okada, M. Balazs, R. Adany, et al. 2008. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J. Leukocyte Biol. 83: 1136-1144.
29. Kezuka, T., and J. W. Streilein. 2000. Analysis of in vivo regulatory properties of T cells activated in vitro by TGFβ2-treated antigen presenting cells. Invest. Ophthalmol. Visual Sci. 41: 1410-1421. (Pubitemid 30261864)
30. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
31. Serafini, P., C. De Santo, I. Marigo, S. Cingarlini, L. Dolcetti, G. Gallina, P. Zanovello, and V. Bronte. 2004. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 53: 64-72.
32. + myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J. Immunol. 165: 779-785.
33. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66: 1123-1131.
34. + myeloid cells. J. Immunol. 166: 5398-5406.
35. Apolloni, E., V. Bronte, A. Mazzoni, P. Serafini, A. Cabrelle, D. M. Segal, H. A. Young, and P. Zanovello. 2000. Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J. Immunol. 165: 6723-6730.
36. + cells. J. Immunol. 161: 5313-5320.
37. Bronte, V., P. Serafini, E. Apolloni, and P. Zanovello. 2001. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J. Immunother. 24: 431-446.
38. Frey, A. B. 2006. Myeloid suppressor cells regulate the adaptive immune response to cancer. J. Clin. Invest. 116: 2587-2590.
39. Taheri, F., J. B. Ochoa, Z. Faghiri, K. Culotta, H. J. Park, M. S. Lan, A. H. Zea, and A. C. Ochoa. 2001. L-Arginine regulates the expression of the T-cell receptor ζ chain (CD3ζ) in Jurkat cells. Clin. Cancer Res. 7: 958s-965s.
40. high suppressive monocytes in experimental autoimmune encephalomyelitis. J. Immunol. 179: 5228-5237.
41. Robertson, M., J. Liversidge, J. V. Forrester, and A. D. Dick. 2003. Neutralizing tumor necrosis factor-α activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest. Ophthalmol. Visual Sci. 44: 3034-3041.
42. Knight, B., G. C. Yeoh, K. L. Husk, T. Ly, L. J. Abraham, C. Yu, J. A. Rhim, and N. Fausto. 2000. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J. Exp. Med. 192: 1809-1818.
43. Dick, A. D., L. Duncan, G. Hale, H. Waldmann, and J. Isaacs. 1998. Neutralizing TNF-α activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J. Autoimmun. 11: 255-264.
44. Korner, H., D. S. Riminton, D. H. Strickland, F. A. Lemckert, J. D. Pollard, and J. D. Sedgwick. 1997. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J. Exp. Med. 186: 1585-1590.
45. Xie, B., A. Laouar, and E. Huberman. 1998. Autocrine regulation of macrophage differentiation and 92-kDa gelatinase production by tumor necrosis factor-α via alpha5 β1 integrin in HL-60 cells. J. Biol. Chem. 273: 11583-11588.
46. Yarilina, A., K. H. Park-Min, T. Antoniv, X. Hu, and L. B. Ivashkiv. 2008. TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat. Immunol. 9: 378-387.